Dr. Gabriel A. Brooks discusses what DPD deficiency is and why it is important for patients with cancer receiving 5-FU or Xeloda to be aware of it. The Food and Drug Administration (FDA) has updated ...

This enzyme, also known as DPD, is usually caused by inherited changes in a particular gene. Currently, there are internationally accepted dosing guidelines for 5-FU, adjusted according to DPD ...

Following conversion to 5-FU, 60–90% of capecitabine is catabolized by dihydropyrimidine dehydrogenase (DPD) ultimately to FBAL and 10–20% is excreted in urine unchanged. It has also been ...

Well-designed studies, with consistent tissue sources and 5-FU regimens, need to be conducted ... Current data suggest that tumors with lower levels of TS and DPD have a greater likelihood of ...